Rare disease had a lot to say in April. Here’s what moved the needle.
Three FDA approvals, a landmark CRISPR Phase 3 readout, and a $180M voucher sale made for a headline-heavy month on the clinical side. Regeneron’s Otarmeni became the first gene therapy cleared for genetic hearing loss. Travere’s FILSPARI ended a long drought for FSGS patients with no approved options. And Intellia’s NTLA-2002 posted an 87% reduction in hereditary angioedema attacks after a single dose — the kind of data that makes regulators and investors pay attention.
Not everything was a win. The FDA’s proposal to yank Tavneos off the market — citing both a reanalysis of pivotal trial data and a growing post-marketing liver toxicity signal — was a stark reminder that approval is never the final word.
On the dealmaking front, acquirers were busy consolidating. Chiesi snapped up KalVista to deepen its HAE franchise, Neurocrine bought into rare endocrinology via Soleno, and LEO Pharma picked up Replay’s gene therapy platform to accelerate its rare skin disease ambitions. The message from the M&A activity is consistent: rare disease remains a buyer’s market for late-stage and platform assets.
1. Clinical news
April delivered a striking concentration of rare disease firsts: the FDA granted its first-ever approval for FSGS, its first gene therapy for genetic hearing loss, and resumed review of what could become the first cell therapy for DMD cardiomyopathy — while a Phase 3 CRISPR readout in HAE signaled that one-time gene editing is crossing from promise into clinical reality. Set against the rare regulatory reversal on Tavneos, the month underscores both the accelerating pace of rare disease innovation and the heightened evidentiary bar regulators are prepared to enforce.
Travere Therapeutics announced full FDA approval of FILSPARI (sparsentan) for focal segmental glomerulosclerosis (FSGS), a rare and progressive kidney disease that can lead to end-stage renal failure. FILSPARI is an oral small-molecule dual receptor antagonist (endothelin receptor antagonist and angiotensin II receptor blocker) that reduces proteinuria and slows kidney disease progression by targeting key pathways involved in glomerular injury and fibrosis. It is used in patients with FSGS, a rare proteinuric kidney disorder characterized by scarring of the kidney’s filtering units, typically affecting adolescents and adults and often progressing to end-stage renal disease. FILSPARI becomes the first and only FDA-approved therapy for FSGS, marking a major milestone in rare nephrology. Approval was supported by clinical evidence demonstrating significant reductions in proteinuria versus active comparator therapy, reinforcing its disease-modifying potential and transitioning the program into full commercial status
Pasithea Therapeutics received FDA Rare Pediatric Disease Designation (RPDD) for PAS-004, an investigational therapy for neurofibromatosis type 1 (NF1), a rare genetic disorder caused by mutations in the NF1 gene and characterized by abnormal cell growth leading to benign and malignant tumors along peripheral nerves, along with multisystem complications. PAS-004 is an investigational targeted small-molecule intended for pediatric and adolescent NF1 patients, a population with high unmet need due to limited disease-modifying treatment options and largely symptom- or tumor-directed management strategies. The RPDD status enables expedited regulatory development pathways and potential eligibility for a Priority Review Voucher upon approval, reinforcing FDA prioritization of therapies for rare pediatric genetic disorders with systemic disease burden and limited disease-modifying options.
The FDA lifted its July 2025 Complete Response Letter and resumed review of Capricor’s BLA for deramiocel (CAP-1002), an allogeneic cardiosphere-derived cell therapy for DMD cardiomyopathy, following submission of Phase 3 HOPE-3 data. The trial (n=106) met its primary endpoint with a 54% slowing of upper limb function decline (PUL v2.0, p=0.029) and a 91% slowing of cardiac decline (LVEF%) versus placebo. Deramiocel’s mutation-agnostic, anti-fibrotic mechanism distinguishes it from existing dystrophin-restoration approaches. If approved, it would be the first cell therapy to address both skeletal and cardiac manifestations of DMD, with a PRV expected upon approval.
Star Therapeutics received FDA Breakthrough Therapy and Rare Pediatric Disease Designations for VGA039, an investigational prophylactic therapy for von Willebrand disease (vWD), a rare inherited bleeding disorder caused by deficiency or dysfunction of von Willebrand factor, leading to impaired platelet adhesion and abnormal bleeding. VGA039 is a biologic developed for pediatric and adult patients with moderate to severe von Willebrand disease, aiming to prevent bleeding episodes rather than treat them episodically. The Breakthrough Therapy designation reflects early clinical evidence suggesting meaningful improvement in bleeding prevention, particularly in prophylactic use settings. The program represents a broader shift in rare hematology toward preventive, long-term disease control strategies, extending beyond traditional on-demand or hemophilia-centered treatment paradigms.
Regeneron Pharmaceuticals announced FDA approval of Otarmeni, an AAV gene therapy for pediatric patients with inherited hearing loss caused by OTOF (otoferlin) mutations. Otarmeni becomes the first gene therapy approved for genetic hearing loss, administered via inner-ear delivery. It uses an AAV (adeno-associated virus) vector to deliver a functional copy of the OTOF gene directly into cochlear hair cells, enabling restoration of otoferlin protein expression required for synaptic vesicle release and auditory signal transmission between inner hair cells and auditory neurons. Clinical data demonstrated meaningful restoration of auditory function, including improvements in hearing thresholds and speech perception outcomes, validating inner-ear gene transfer as a clinically viable therapeutic platform.
Intellia Therapeutics reported positive Phase 3 results for NTLA-2002, an in vivo CRISPR-based gene editing therapy targeting hereditary angioedema (HAE), a rare disorder characterized by recurrent and potentially life-threatening swelling attacks. The study demonstrated an approximately 87% reduction in monthly attack rate, with a substantial proportion of patients remaining attack-free following a single administration. Safety findings were consistent with earlier clinical stages, supporting regulatory filing and positioning NTLA-2002 as a potential first-in-class one-time treatment that could redefine HAE management.
Rocket Pharmaceuticals sold its Rare Pediatric Disease Priority Review Voucher for $180 million after FDA approval of Kresladi (marnetegragene autotemcel) for severe leukocyte adhesion deficiency-I (LAD-I). Kresladi is an autologous stem cell gene therapy designed to restore immune cell function in pediatric patients with this life-threatening primary immunodeficiency. The voucher sale provides Rocket with substantial non-dilutive capital to support commercialization and pipeline development.
FDA’s Center for Drug Evaluation and Research (CDER) formally proposed to withdraw approval of Tavneos (avacopan), an oral complement inhibitor approved in 2021 as an adjunctive treatment for adults with severe active ANCA-associated vasculitis (AAV) — a rare autoimmune disease-causing damage to small blood vessels and progressive organ failure. The proposal, issued on April 27 and published in the Federal Register on April 30, 2026, is grounded in two findings: a lack of substantial evidence of effectiveness based on new information, and the inclusion of untrue statements of material fact in ChemoCentryx’s original NDA — specifically concerning the re-adjudication of primary endpoint results for 9 patients in the pivotal ADVOCATE trial. FDA also cited serious post-marketing hepatotoxicity concerns, including 76 reported cases of drug-induced liver injury (DILI), 54 hospitalizations, 8 deaths, and 7 biopsy-confirmed cases of vanishing bile duct syndrome (VBDS) since approval. ChemoCentryx (an Amgen subsidiary) has until June 1, 2026 to request a formal hearing. Amgen contests the Agency’s position, stating it remains confident in Tavneos’ benefit-risk profile based on clinical data and real-world evidence from over 7,000 treated patients.
The European Commission, acting on a positive EMA COMP opinion, granted Orphan Drug Designation to SGT-003 for DMD, adding to existing FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations, as well as the UK ILAP designation. SGT-003 is a next-generation AAV gene therapy delivering a microdystrophin construct with nNOS-localizing R16/17 domains via the novel POLARIS-101 capsid, designed to improve muscle blood flow and reduce disease progression. It is currently being evaluated in the Phase 1/2 INSPIRE DUCHENNE trial, which reported positive interim data at the 2026 MDA Annual Meeting, and the simultaneously running Phase 3 IMPACT DUCHENNE randomized, double-blind, placebo-controlled trial in ambulatory boys aged 7 to <12, both designed to support multinational regulatory submissions.
Expression Therapeutics received FDA Fast Track and Rare Pediatric Disease Designations for its investigational stem cell therapy targeting hemophilia A, a rare bleeding disorder caused by factor VIII deficiency. The program aims to provide durable or potentially curative correction via stem cell–based engraftment approaches. The designations enable accelerated development and regulatory interaction, while also offering eligibility for a Priority Review Voucher upon potential approval.
2. Financings & Partnerships
Two of the three deals this month — Neurocrine’s $2.9B acquisition of Soleno and Chiesi’s $1.9B buyout of KalVista — were acquisitions of already-approved, commercially launched rare disease products, reflecting the premium large players are willing to pay to eliminate development risk and accelerate revenue growth in specialty markets. LEO Pharma’s $50M early-stage bet on Replay’s preclinical gene therapy platform stands in deliberate contrast, pointing to a bifurcated M&A landscape where acquirers are simultaneously paying up for proven assets and locking in next-generation platforms before the field matures.
Deal: Neurocrine Biosciences announced a definitive agreement to acquire Soleno Therapeutics in an all-cash transaction valued at $2.9 billion ($53.00 per share, a 34% premium to Soleno’s April 2 closing price). The acquisition centers on VYKAT XR (diazoxide choline extended-release tablets), an FDA-approved, first-in-class oral therapy for hyperphagia in Prader-Willi syndrome (PWS) launched in Q2 2025, which generated $190 million in revenue in its first year of commercialization. The transaction marks Neurocrine’s largest M&A deal to date and is expected to close within 90 days.
Type: M&A / Rare disease and endocrinology portfolio expansion
Deal: Chiesi Group announced a definitive agreement to acquire KalVista Pharmaceuticals in an all-cash transaction valued at approximately $1.9 billion ($27.00 per share, a 36% premium to KalVista’s 30-day VWAP as of April 28, 2026). The acquisition is centered on EKTERLY (sebetralstat), the first approved oral, on-demand treatment for hereditary angioedema (HAE), launched in the U.S. in July 2025 and generating $49 million in its first year of sales, with approvals also in the EU, UK, and Japan. A pediatric Phase 3 trial (KONFIDENT-KID) has reported positive interim results. The transaction — the largest in Chiesi’s 90-year history — is expected to close in Q3 2026.
Type: M&A / Rare disease portfolio expansion (hereditary angioedema)
Deal: LEO Pharma announced a definitive agreement to acquire Replay for an upfront payment of $50 million, plus undisclosed milestone payments and tiered single-digit royalties on future product sales. The acquisition adds Replay’s high-payload herpes simplex virus (HSV) gene therapy platform to LEO Pharma’s rare dermatology pipeline, with a lead program currently in preclinical development for dystrophic epidermolysis bullosa (DEB), a severe genetic skin disorder. The therapy is formulated as a topical gel designed to deliver large therapeutic genes directly into skin cells. LEO Pharma noted the deal will increase development spending, revising its 2026 adjusted EBITDA margin outlook to 15–18%.
Type: M&A / Rare dermatology gene therapy expansion
3. Research breakthroughs
Mapping Every Mutation in a Rare Neurodevelopmental Gene — At Single-Nucleotide Resolution
A study published in Nature delivers one of the most detailed functional maps ever created for a rare disease gene, with direct consequences for patient diagnosis and a surprise: a second, previously unrecognized disorder hiding in the same gene.
RNU4-2 encodes a small non-coding RNA that is a core component of the spliceosome — the molecular machinery responsible for correctly processing messenger RNA. Mutations in this gene were recently shown to cause ReNU syndrome, a severe neurodevelopmental disorder characterized by intellectual disability, developmental delay, hypotonia, seizures, and impaired motor and speech development. Estimates suggest the condition affects tens of thousands of individuals worldwide, yet many cases likely remain undiagnosed or misclassified due to difficulty interpreting uncertain genetic results.
To address this, researchers at the Francis Crick Institute used a technique called saturation genome editing (SGE), systematically introducing and testing virtually every possible single-letter change across the entire RNU4-2 gene in human cells, then directly measuring each variant’s functional impact. This experimental approach generates real-world functional evidence rather than relying on computational prediction — and the resulting SGE scores markedly outperformed standard in silico tools at distinguishing disease-causing variants from benign ones.
The clinical implications are twofold. First, the data resolves a large proportion of variants of uncertain significance in ReNU syndrome patients, enabling more confident diagnoses. Second, and perhaps most unexpectedly, the study identifies a second, distinct neurodevelopmental disorder caused by more severe, biallelic (recessive) loss of RNU4-2 function — broadening the disease spectrum associated with this gene and likely uncovering a new population of patients currently without a molecular diagnosis.
Taken together, the findings establish that the same gene can give rise to fundamentally different diseases depending on how severely its function is disrupted, and they lay a functional foundation to support both improved clinical interpretation and future therapeutic development.
Base Editing Rescues Liver Function in Zellweger Spectrum Disorder
Scientists at Broad Institute used base editing to correct a disease-causing mutation in the PEX1 gene in human cells and mice, restoring the function of peroxisomes — organelles that malfunction in Zellweger spectrum disorder, a rare, life-threatening condition causing liver and brain damage. Zellweger spectrum disorder affects roughly 1 in 50,000 to 90,000 births in North America and currently lacks any curative therapies. Demonstrating that base editing can safely reverse the condition’s pathology and clear toxic metabolites establishes a critical precedent for translating precision genetic medicine into viable clinical interventions. Notably, the study, which began in 2020, guided the team toward a specific deaminase enzyme component that was subsequently used in 2025 to treat baby KJ Muldoon — the world’s first recipient of a personalized gene editing treatment.
Upcoming events
📅 May 18–19, 2026 — 15th World Rare Diseases Congress 2026 — Prague, Czech Republic Global forum covering research, policy, and clinical care for rare and orphan diseases, bringing together scientists, clinicians, advocates, industry, and regulators.
📅 June 3–4, 2026 — European Conference on Rare Diseases & Orphan Products (ECRD 2026) — Prague, CZ & Online The flagship European policy and advocacy event for rare diseases, led by EURORDIS, addressing healthcare access, research, holistic care, and patient engagement.
📅 June 9–11, 2026 — World Orphan Drug Congress USA 2026 — Boston, MA, USA One of the largest global gatherings dedicated to rare and orphan drug development, bringing together industry leaders, regulators, investors, and patient advocates.
📅 June 17–18, 2026 — 7th International Conference on Rare Diseases (RARE2026) — Kraków, Poland Scientific conference covering gene therapy, omics, newborn screening, and translational research with global participation and expert speakers in the rare disease field.
📅 September 9–10, 2026 — Clinical Trials in Rare Diseases Conference 2026 — Princeton Marriott at Forrestal, Princeton, NJ, USA Focused on innovative clinical trial design, patient recruitment, and regulatory strategies for rare disease therapeutics, connecting academia, biotech, and regulators.
📅 September 14–15, 2026 — 2nd European Congress on Rare Diseases and Orphan Drugs 2026 — London, United Kingdom International forum featuring researchers, clinicians, policymakers, and pharmaceutical experts discussing new advances in diagnosis, orphan drug development, and health policy.
📅 October 22–23, 2026 — 4th International Conference on Rare Diseases and Orphan Drugs 2026 — Barcelona, Spain Global scientific conference themed “From Discovery to Cure: Transforming Rare Disease Care,” highlighting cutting‑edge research, therapeutic innovation, and patient‑centered care models.
📅 October 25–27, 2026 — NORD Rare Diseases & Orphan Products Breakthrough Summit 2026 — Washington, DC, USA Hosted by the National Organization for Rare Disorders (NORD), this premier U.S. summit unites patients, researchers, regulators, and biotech innovators to accelerate progress in rare disease treatments and policy.
📅 October 26–28, 2026 — World Orphan Drug Congress Europe — Amsterdam, Netherlands Leading global forum dedicated to rare disease drug development, orphan drug regulation, and market access, featuring stakeholders from biotech, pharma, patient advocacy groups, and regulators discussing advanced therapies including gene therapy, CRISPR, and RNA-based treatments.
📅 November 10–12, 2026 — BIO-Europe 2026 — Cologne, Germanny One of the largest global biotech partnering conferences, bringing together biopharma companies, investors, and rare disease developers to accelerate licensing deals, cross-border partnerships, and orphan drug collaborations across gene therapy, RNA therapeutics, and ultra-rare indications.